Login Register Cart 0
Generic placeholder image

Current Molecular Pharmacology

Editor-in-Chief

ISSN (Print): 1874-4672
ISSN (Online): 1874-4702

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

MiR-129-2-3p Inhibits Esophageal Carcinoma Cell Proliferation, Migration, and Invasion via Targeting DNMT3B

Author(s): Xuyang Peng, Xuhui Wu, Gongzhi Wu, Chongxiong Peng, Bin Huang, Mingjiang Huang, Jianyang Ding, Chaofan Mao and Huaizhong Zhang*

Volume 16, Issue 1, 2023

Published on: 13 May, 2022

Article ID: e080322201884 Pages: 8

DOI: 10.2174/1874467215666220308122716

Price: $65

Abstract

Purpose: The study aims to explore the regulatory mechanism of miR-129-2-3p underlying esophageal carcinoma (EC) cell progression and generate new ideas for targeted treatment of EC.

Methods: Mature miRNA expression data and total RNA sequencing data of EC in the TCGAESCA dataset were utilized to explore differentially expressed miRNAs (DEmiRNAs). StarBase database was then utilized to predict targets of miRNA. MiR-129-2-3p and DNMT3B expression in EC cell lines was assayed through qRT-PCR and Western blot. CCK-8, scratch healing, and transwell assays were conducted to assess the impact of miR-129-2-3p on EC cell phenotypes. In addition, a dual-luciferase assay was completed to identify the binding relationship between DNMT3B and miR-129-2-3p.

Results: MiR-129-2-3p was noticeably less expressed in EC cell lines, while DNMT3B was highly expressed. MiR-129-2-3p could bind to DNMT3B. Furthermore, in vitro functional experiments uncovered that overexpressed miR-129-2-3p repressed EC cell progression while further overexpressing DNMT3B would restore the above inhibitory effect.

Conclusion: MiR-129-2-3p is a cancer repressor in EC cells, and it could target DNMT3B, thus hampering the progression of EC cells.

Keywords: miR-129-2-3p, DNMT3B, esophageal carcinoma, proliferation, migration, invasion.

Graphical Abstract

[1]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136(5), E359-E386.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[2]
Jiao, W.; Zhang, J.; Wei, Y.; Feng, J.; Ma, M.; Zhao, H.; Wang, L.; Jiao, W. MiR-139-5p regulates VEGFR and downstream sig-naling pathways to inhibit the development of esophageal cancer. Dig. Liver Dis., 2019, 51(1), 149-156.
[http://dx.doi.org/10.1016/j.dld.2018.07.017] [PMID: 30245290]
[3]
Liu, J.; Xue, N.; Guo, Y.; Niu, K.; Gao, L.; Zhang, S.; Gu, H.; Wang, X.; Zhao, D.; Fan, R. CircRNA_100367 regulated the ra-diation sensitivity of esophageal squamous cell carcinomas through miR-217/Wnt3 pathway. Aging (Albany NY), 2019, 11(24), 12412-12427.
[http://dx.doi.org/10.18632/aging.102580] [PMID: 31851619]
[4]
Anvari, K.; Sima, H.R.; Seilanian Toussi, M.; Anvari, A.; Sha-hidsales, S.; Memar, B.; Aledavoud, S.A.; Forghani, M.N.; Abdollahi, A.; Ghaffarzadegan, K. EGFR expression in patients with esophageal squamous cell carcinoma and its association with pathologic response to preoperative chemoradiotherapy: A study in northeastern Iran. Arch. Iran Med., 2017, 20(4), 240-245. http://dx.doi.org/0172004/AIM.0010
[PMID: 28412829]
[5]
DeSantis, C.E.; Lin, C.C.; Mariotto, A.B.; Siegel, R.L.; Stein, K.D.; Kramer, J.L.; Alteri, R.; Robbins, A.S.; Jemal, A. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin., 2014, 64(4), 252-271.
[http://dx.doi.org/10.3322/caac.21235] [PMID: 24890451]
[6]
Rustgi, A.K.; El-Serag, H.B. Esophageal carcinoma. N. Engl. J. Med., 2014, 371(26), 2499-2509.
[http://dx.doi.org/10.1056/NEJMra1314530] [PMID: 25539106]
[7]
McCabe, M.L.; Dlamini, Z. The molecular mechanisms of oe-sophageal cancer. Int. Immunopharmacol., 2005, 5(7-8), 1113-1130.
[http://dx.doi.org/10.1016/j.intimp.2004.11.017] [PMID: 15914317]
[8]
Yu, X.; Li, Z. The role of microRNAs expression in laryngeal cancer. Oncotarget, 2015, 6(27), 23297-23305.
[http://dx.doi.org/10.18632/oncotarget.4195] [PMID: 26079642]
[9]
Jili, S.; Eryong, L.; Lijuan, L.; Chao, Z. RUNX3 inhibits larynge-al squamous cell carcinoma malignancy under the regulation of miR-148a-3p/DNMT1 axis. Cell Biochem. Funct., 2016, 34(8), 597-605.
[http://dx.doi.org/10.1002/cbf.3233] [PMID: 27859417]
[10]
Li, B.X.; Yu, Q.; Shi, Z.L.; Li, P.; Fu, S. Circulating microRNAs in esophageal squamous cell carcinoma: Association with lo-coregional staging and survival. Int. J. Clin. Exp. Med., 2015, 8(5), 7241-7250.
[PMID: 26221263]
[11]
Mao, Y.; Li, L.; Liu, J.; Wang, L.; Zhou, Y. MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1. Oncotarget, 2016, 7(32), 51223-51236.
[http://dx.doi.org/10.18632/oncotarget.9981] [PMID: 27323412]
[12]
Zhou, B.; Sun, C.; Hu, X.; Zhan, H.; Zou, H.; Feng, Y.; Qiu, F.; Zhang, S.; Wu, L.; Zhang, B. MicroRNA-195 suppresses the progression of pancreatic cancer by targeting DCLK1. Cell. Physiol. Biochem., 2017, 44(5), 1867-1881.
[http://dx.doi.org/10.1159/000485876] [PMID: 29224010]
[13]
Huang, L.L.; Huang, L.W.; Wang, L.; Tong, B.D.; Wei, Q.; Ding, X.S. Potential role of miR-139-5p in cancer diagnosis, prognosis and therapy. Oncol. Lett., 2017, 14(2), 1215-1222.
[http://dx.doi.org/10.3892/ol.2017.6351] [PMID: 28789336]
[14]
Zhou, Y.W.; Zhang, H.; Duan, C.J.; Gao, Y.; Cheng, Y.D.; He, D.; Li, R.; Zhang, C.F. miR-675-5p enhances tumorigenesis and metastasis of esophageal squamous cell carcinoma by targeting REPS2. Oncotarget, 2016, 7(21), 30730-30747.
[http://dx.doi.org/10.18632/oncotarget.8950] [PMID: 27120794]
[15]
Qi, B.; Wang, Y.; Chen, Z.J.; Li, X.N.; Qi, Y.; Yang, Y.; Cui, G.H.; Guo, H.Z.; Li, W.H.; Zhao, S. Down-regulation of miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell proliferation by activating the Wnt signaling pathway. World J. Gastroenterol., 2017, 23(45), 7965-7977.
[http://dx.doi.org/10.3748/wjg.v23.i45.7965] [PMID: 29259372]
[16]
Lindner, K.; Eichelmann, A.K.; Matuszcak, C.; Hussey, D.J.; Haier, J.; Hummel, R. Complex epigenetic regulation of chemo-therapy resistance and biohlogy in esophageal squamous cell carcinoma via MicroRNAs. Int. J. Mol. Sci., 2018, 19(2), E499.
[http://dx.doi.org/10.3390/ijms19020499] [PMID: 29414899]
[17]
Tang, X.; Tang, J.; Liu, X.; Zeng, L.; Cheng, C.; Luo, Y.; Li, L.; Qin, S.L.; Sang, Y.; Deng, L.M.; Lv, X.B. Downregulation of miR-129-2 by promoter hypermethylation regulates breast can-cer cell proliferation and apoptosis. Oncol. Rep., 2016, 35(5), 2963-2969.
[http://dx.doi.org/10.3892/or.2016.4647] [PMID: 26935022]
[18]
Xiao, Y.; Li, X.; Wang, H.; Wen, R.; He, J.; Tang, J. Epigenetic regulation of miR-129-2 and its effects on the proliferation and invasion in lung cancer cells. J. Cell. Mol. Med., 2015, 19(9), 2172-2180.
[http://dx.doi.org/10.1111/jcmm.12597] [PMID: 26081366]
[19]
Wang, D.; Luo, L.; Guo, J. miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer. Med. Oncol., 2014, 31(8), 98.
[http://dx.doi.org/10.1007/s12032-014-0098-1] [PMID: 25008064]
[20]
Fan, J.; Liu, Z.; Mao, X.; Tong, X.; Zhang, T.; Suo, C.; Chen, X. Global trends in the incidence and mortality of esophageal can-cer from 1990 to 2017. Cancer Med., 2020, 9(18), 6875-6887.
[http://dx.doi.org/10.1002/cam4.3338] [PMID: 32750217]
[21]
Parkin, D.M.; Bray, F.I.; Devesa, S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer, 2001, 37(Suppl. 8), S4-S66.
[http://dx.doi.org/10.1016/S0959-8049(01)00267-2] [PMID: 11602373]
[22]
Trichopoulos, D. The unequal burden of cancer. BMJ, 2000, 320(7230), 321.
[http://dx.doi.org/10.1136/bmj.320.7230.321] [PMID: 10650051]
[23]
Guo, J.; Wang, M.; Liu, X. MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. J. Exp. Clin. Cancer Res., 2015, 34(1), 91.
[http://dx.doi.org/10.1186/s13046-015-0209-7] [PMID: 26338045]
[24]
Kawano, M.; Tanaka, K.; Itonaga, I.; Ikeda, S.; Iwasaki, T.; Tsumura, H. microRNA-93 promotes cell proliferation via tar-geting of PTEN in Osteosarcoma cells. J. Exp. Clin. Cancer Res., 2015, 34(1), 76.
[http://dx.doi.org/10.1186/s13046-015-0192-z] [PMID: 26243299]
[25]
Sannigrahi, M.K.; Sharma, R.; Singh, V.; Panda, N.K.; Rattan, V.; Khullar, M. DNA methylation regulated microRNAs in HPV-16-induced head and neck squamous cell carcinoma (HNSCC). Mol. Cell. Biochem., 2018, 448(1-2), 321-333.
[http://dx.doi.org/10.1007/s11010-018-3336-6] [PMID: 29455435]
[26]
Robertson, K.D. DNA methylation and human disease. Nat. Rev. Genet., 2005, 6(8), 597-610.
[http://dx.doi.org/10.1038/nrg1655] [PMID: 16136652]
[27]
Robertson, K.D.; Wolffe, A.P. DNA methylation in health and disease. Nat. Rev. Genet., 2000, 1(1), 11-19.
[http://dx.doi.org/10.1038/35049533] [PMID: 11262868]
[28]
Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 2002, 3(6), 415-428.
[http://dx.doi.org/10.1038/nrg816] [PMID: 12042769]
[29]
Bestor, T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet., 2000, 9(16), 2395-2402.
[http://dx.doi.org/10.1093/hmg/9.16.2395] [PMID: 11005794]
[30]
Lei, H.; Oh, S.P.; Okano, M.; Jüttermann, R.; Goss, K.A.; Jae-nisch, R.; Li, E. De novo DNA cytosine methyltransferase activi-ties in mouse embryonic stem cells. Development, 1996, 122(10), 3195-3205.
[http://dx.doi.org/10.1242/dev.122.10.3195] [PMID: 8898232]
[31]
Li, E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet., 2002, 3(9), 662-673.
[http://dx.doi.org/10.1038/nrg887] [PMID: 12209141]
[32]
Wang, J.C.; Wang, Z.; Fan, Y.X.; Si, Y.Q.; Wang, J.X. DNA me-thyltransferase 3b silencing affects locus-specific DNA methyla-tion and inhibits proliferation, migration and invasion in human hepatocellular carcinoma SMMC-7721 and BEL-7402 cells. Oncol. Lett., 2015, 9(6), 2499-2506.
[http://dx.doi.org/10.3892/ol.2015.3077] [PMID: 26137097]
[33]
Jin, B.; Robertson, K.D. DNA methyltransferases, DNA damage repair, and cancer. Adv. Exp. Med. Biol., 2013, 754, 3-29.
[http://dx.doi.org/10.1007/978-1-4419-9967-2_1] [PMID: 22956494]
[34]
Wang, L.; Wang, Z.; Huang, L.; Wu, C.; Zhang, B. MiR-29b sup-presses proliferation and mobility by targeting SOX12 and DNMT3b in pancreatic cancer. Anticancer Drugs, 2019, 30(3), 281-288.
[http://dx.doi.org/10.1097/CAD.0000000000000719] [PMID: 30601190]
[35]
Wu, S.; Xie, J.; Shi, H.; Wang, Z.W. miR-492 promotes chemo-resistance to CDDP and metastasis by targeting inhibiting DNMT3B and induces stemness in gastric cancer. Biosci. Rep., 2020, 40(3), BSR20194342.
[http://dx.doi.org/10.1042/BSR20194342] [PMID: 32065219]

Rights & Permissions Print Cite
Article Metrics
8
© 2024 Bentham Science Publishers | Privacy Policy